Efficacy and safety of mizolastine 10 mg in a placebo‐controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR study¹

Abstract

Mizolastine (10 mg daily) is confirmed as an effective and well tolerated agent, comparable to loratadine and superior to placebo, for the management of CIU. Mizolastine acted as rapidly as loratadine in improving urticarial symptoms from the first day of treatment.